Permanent Forum on International Pharmaceutical Crime: Protecting public health globally

The Permanent Forum on International Pharmaceutical Crime (PFIPC) is an international enforcement forum aimed at protecting public health through the exchange of information and ideas to foster mutual cooperation.

Learn More

Our Mission

Our mission is to foster international cooperation in the fight against pharmaceutical crime. We strive to protect public health by sharing knowledge, resources, and best practices among enforcement agencies worldwide.

Learn more about our initiatives, the work we do, and how we are making a difference globally. Stay informed about our latest efforts to combat counterfeit and illegal pharmaceuticals.

Live event on safety on compounded GLP-1s

Join us in person in Washington DC on Wednesday July 26, 2026 for Axios Live "Examining Risk and Regulation in the GLP-1 Landscape" Speakers include The Honorable Nikki Budzinski (IL-13), Scott Kahan, M.D., M.P.H., F.T.O.S., Shabbir Imber Safdar, CFE, The Honorable Rudy Yakym (IN-02)

July 13, 2026: Researchers find telehealth platforms prioritize “quick prescriptions over comprehensive care”

The study found that 91.8% of the platforms issued a prescription. In their questionnaire, which was used on every platorm, 98% asked about medical conditions, 93.9% asked about medications and allergies, and only 55.1% asked about eating disorder history.

The five risks of taking unapproved peptides

The FDA is reconsidering adding a dozen peptides—seven in July; another four next February—to its Section 503A bulk drug substances list after excluding them over safety concerns in 2023. The review is happening at a time when Americans are turning to peptides at an unprecedented rate, driven by grifters in the online wellness space, who push these products for a profit without any clinical evidence they are either safe or effective.

Partnership for Safe Medicines urges FDA advisory committee to reject compounding of unapproved peptides

On July 23-24, the FDA will evaluate seven peptides for custom pharmacy compounding. Citing a critical deficit in human safety data, widespread consumer confusion, and systemic supply chain vulnerabilities, PSM urges the committee to block mass compounding and protect patient safety.

Get Involved

Join us in our mission to protect public health. Learn more about how you can contribute to our efforts or collaborate with us. Your support and involvement are crucial to our success.